AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Canopy Growth Corporation
Video analysis: CGC
All videosNo video analysis for this stock yet. Request one from our team.
News: CGC
Canopy Growth (NASDAQ:CGC) vs. Clene (NASDAQ:CLNN) Financial Comparison
Canopy Growth (NASDAQ: CGC - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Valuation and Earnings This table compares Canopy Growth
Canopy Growth Corporation (NASDAQ:CGC) Receives Average Recommendation of “Hold” from Brokerages
Shares of Canopy Growth Corporation (NASDAQ: CGC - Get Free Report) have been assigned a consensus rating of "Hold" from the five ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating
Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges.
Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted.
Canopy Growth's revenue increased 13% year over year in its most recent fiscal quarter. Adjusted gross margin improved, while EBITDA losses narrowed sharply.
Should You Buy Canopy Growth Stock on the Rebound?
Canopy Growth is a large Canadian marijuana company. Over the past year, it has strengthened its financial position and made an acquisition.
Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?
Tilray is seeing more revenue from beverages than from cannabis. Canopy's debt situation drags down its growth potential.
3 Top Marijuana Stocks to Watch in September 2026
The cannabis industry is entering September, and investors are once again searching for opportunities across the sector. After years of volatility, several marijuana companies are showing signs of stronger financial performance. Revenue is improving for some operators. Meanwhile, others are cutting costs, strengthening margins, and expanding internationally. That combination could put marijuana stocks back on investors' radar. However, this is no longer simply a story about rapid expansion. Investors are becoming more selective about which cannabis companies deserve their attention. Today, profitability matters. Cash flow matters. Additionally, investors want companies with strong brands and opportunities beyond their existing markets. International cannabis growth has become particularly important. Europe continues expanding its medical cannabis industry. As a result, Canadian producers are positioning themselves to capture growing international demand. Meanwhile, the United States remains an important potential catalyst. Changes to federal cannabis regulations could eventually reshape the industry's investment landscape.
Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?
Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.
